PT1114166E - Metodo para regular negativamente a actividade do ligando da osteoprotegerina - Google Patents
Metodo para regular negativamente a actividade do ligando da osteoprotegerinaInfo
- Publication number
- PT1114166E PT1114166E PT99942778T PT99942778T PT1114166E PT 1114166 E PT1114166 E PT 1114166E PT 99942778 T PT99942778 T PT 99942778T PT 99942778 T PT99942778 T PT 99942778T PT 1114166 E PT1114166 E PT 1114166E
- Authority
- PT
- Portugal
- Prior art keywords
- opgl
- ligand
- nucleic acids
- osteoprotegerine
- activity
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 102000014128 RANK Ligand Human genes 0.000 abstract 6
- 108010025832 RANK Ligand Proteins 0.000 abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801164 | 1998-09-15 | ||
| US10289698P | 1998-10-02 | 1998-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1114166E true PT1114166E (pt) | 2005-08-31 |
Family
ID=26065320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99942778T PT1114166E (pt) | 1998-09-15 | 1999-09-13 | Metodo para regular negativamente a actividade do ligando da osteoprotegerina |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6645500B1 (pt) |
| EP (1) | EP1114166B1 (pt) |
| JP (1) | JP2002525060A (pt) |
| KR (1) | KR100671036B1 (pt) |
| CN (1) | CN1318105A (pt) |
| AT (1) | ATE291628T1 (pt) |
| AU (1) | AU754971B2 (pt) |
| CA (1) | CA2343654A1 (pt) |
| CZ (1) | CZ2001789A3 (pt) |
| DE (1) | DE69924392T2 (pt) |
| EE (1) | EE200100149A (pt) |
| ES (1) | ES2239457T3 (pt) |
| HK (1) | HK1040261A1 (pt) |
| HR (1) | HRP20010188A2 (pt) |
| HU (1) | HUP0103578A3 (pt) |
| ID (1) | ID28386A (pt) |
| IL (2) | IL141588A0 (pt) |
| NO (1) | NO20011304L (pt) |
| NZ (1) | NZ510508A (pt) |
| PL (1) | PL196790B1 (pt) |
| PT (1) | PT1114166E (pt) |
| SK (1) | SK3062001A3 (pt) |
| TR (1) | TR200100737T2 (pt) |
| WO (1) | WO2000015807A1 (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO128635A2 (ro) * | 1997-04-16 | 2013-07-30 | Amgen Inc. | Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| AU754971B2 (en) * | 1998-09-15 | 2002-11-28 | Pharmexa A/S | Method for down-regulating osteoprotegerin ligand activity |
| GB9908263D0 (en) * | 1999-04-13 | 1999-06-02 | Binding Site The Limited | Eliciting improved immune responses |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
| CA2380007A1 (en) * | 1999-07-28 | 2001-02-08 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
| AU7615600A (en) * | 1999-09-27 | 2001-04-30 | Eli Lilly And Company | Osteoclast differentiation factor regulatory region |
| AUPQ314799A0 (en) * | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
| AU783144B2 (en) * | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
| BR0108566A (pt) * | 2000-02-21 | 2002-11-19 | Pharmexa As | Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico |
| EP1257648B2 (en) † | 2000-02-23 | 2016-09-14 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
| US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| EP1283721A4 (en) * | 2000-05-26 | 2004-07-07 | Smithkline Beecham Corp | ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS |
| JP2004520011A (ja) * | 2000-08-21 | 2004-07-08 | スミスクライン・ビーチャム・コーポレイション | Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体 |
| WO2002024228A1 (fr) * | 2000-09-21 | 2002-03-28 | Center For Advanced Science And Technology Incubation, Ltd. | Méthode de régulation de la formation d'ostéoclastes |
| DE01973455T1 (de) | 2000-09-22 | 2004-04-22 | Immunex Corp., Seattle | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| EP1385532A4 (en) * | 2001-03-22 | 2004-12-15 | Barnes Jewish Hospital | STIMULATION OF THE OSTEOGENESIS WITH RANG-LIGAND FUSION PROTEINS |
| ES2337716T3 (es) | 2001-04-03 | 2010-04-28 | Societe Des Produits Nestle S.A. | Osteoprotegerina en la leche. |
| ATE464068T1 (de) * | 2001-06-26 | 2010-04-15 | Amgen Fremont Inc | Antikörper gegen opgl |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| US20030109444A1 (en) * | 2001-10-12 | 2003-06-12 | Jonathan Lam | Bone anti-resorptive compounds |
| JP4336467B2 (ja) * | 2001-10-15 | 2009-09-30 | 株式会社林原生物化学研究所 | 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法 |
| US7381792B2 (en) | 2002-01-04 | 2008-06-03 | Xencor, Inc. | Variants of RANKL protein |
| WO2003057856A2 (en) | 2002-01-04 | 2003-07-17 | Xencor | Dominant negative proteins and methods thereof |
| WO2003059281A2 (en) * | 2002-01-04 | 2003-07-24 | Xencor | Novel variants of rankl protein |
| JP4761710B2 (ja) | 2002-04-05 | 2011-08-31 | アムジェン インコーポレイテッド | 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体 |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| US7462700B2 (en) | 2002-12-10 | 2008-12-09 | Schering-Plough Animal Health Corporation | Canine RANKL and methods for preparing and using the same |
| EP1750761A1 (en) * | 2004-06-02 | 2007-02-14 | Cytos Biotechnology AG | Medical uses of carrier conjugates of non-human tnf-peptides |
| US20080107597A1 (en) * | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
| WO2008088594A2 (en) * | 2007-01-12 | 2008-07-24 | Anaptysbio, Inc. | Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species |
| CN101434656B (zh) * | 2007-11-16 | 2011-12-14 | 首都医科大学 | Opg-hsp70融合蛋白的制备方法及用途 |
| WO2009154770A2 (en) * | 2008-06-18 | 2009-12-23 | The Texas A & M University System | Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage |
| WO2011128892A2 (en) * | 2010-04-12 | 2011-10-20 | Protea Vaccine Technologies Ltd. | Modified forms of pneumococcal surface immunogenic protein b (psipb) |
| CN107286244B (zh) * | 2016-04-11 | 2021-10-08 | 北京普纳生物科技有限公司 | 抗免疫检查点pd-l1和pd-l2肿瘤疫苗 |
| CN107286245B (zh) * | 2016-04-11 | 2021-10-08 | 北京普纳生物科技有限公司 | Pd-l1和pd-l2重组蛋白及其用途 |
| CN108498786A (zh) * | 2018-02-13 | 2018-09-07 | 南昌大学第二附属医院 | 载骨保护素的缓释纳米粒及其制备方法和应用 |
| KR102154637B1 (ko) * | 2018-11-12 | 2020-09-10 | 조선대학교산학협력단 | Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물 |
| WO2024054566A1 (en) * | 2022-09-07 | 2024-03-14 | The Regents Of The University Of California | Treatment of cancer by blockade of osteoprotegerin |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1237764B (it) * | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| DE4496393T1 (de) | 1993-08-27 | 1996-11-21 | Dow Chemical Co | Verfahren zur Trennung von Enantiomeren |
| EP0755444A4 (en) * | 1994-04-01 | 1998-01-14 | Univ Utah | MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA |
| US6340459B1 (en) * | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| EP1114864B9 (en) * | 1996-12-13 | 2013-05-08 | Schering Corporation | Mammalian cell surface antigens, related reagents |
| EP2371962A3 (en) * | 1996-12-23 | 2011-12-21 | Immunex Corporation | Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| RO128635A2 (ro) * | 1997-04-16 | 2013-07-30 | Amgen Inc. | Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp |
| AU754971B2 (en) * | 1998-09-15 | 2002-11-28 | Pharmexa A/S | Method for down-regulating osteoprotegerin ligand activity |
-
1999
- 1999-09-13 AU AU56173/99A patent/AU754971B2/en not_active Ceased
- 1999-09-13 CA CA002343654A patent/CA2343654A1/en not_active Abandoned
- 1999-09-13 IL IL14158899A patent/IL141588A0/xx unknown
- 1999-09-13 DE DE69924392T patent/DE69924392T2/de not_active Expired - Fee Related
- 1999-09-13 ID IDW20010822A patent/ID28386A/id unknown
- 1999-09-13 ES ES99942778T patent/ES2239457T3/es not_active Expired - Lifetime
- 1999-09-13 PL PL346698A patent/PL196790B1/pl not_active IP Right Cessation
- 1999-09-13 TR TR2001/00737T patent/TR200100737T2/xx unknown
- 1999-09-13 SK SK306-2001A patent/SK3062001A3/sk not_active Application Discontinuation
- 1999-09-13 KR KR1020017003379A patent/KR100671036B1/ko not_active IP Right Cessation
- 1999-09-13 CN CN99810872A patent/CN1318105A/zh active Pending
- 1999-09-13 WO PCT/DK1999/000481 patent/WO2000015807A1/en active IP Right Grant
- 1999-09-13 EE EEP200100149A patent/EE200100149A/xx unknown
- 1999-09-13 EP EP99942778A patent/EP1114166B1/en not_active Expired - Lifetime
- 1999-09-13 JP JP2000570334A patent/JP2002525060A/ja active Pending
- 1999-09-13 NZ NZ510508A patent/NZ510508A/en unknown
- 1999-09-13 PT PT99942778T patent/PT1114166E/pt unknown
- 1999-09-13 AT AT99942778T patent/ATE291628T1/de not_active IP Right Cessation
- 1999-09-13 CZ CZ2001789A patent/CZ2001789A3/cs unknown
- 1999-09-13 HU HU0103578A patent/HUP0103578A3/hu unknown
- 1999-09-15 US US09/396,937 patent/US6645500B1/en not_active Expired - Fee Related
-
2001
- 2001-02-22 IL IL141588A patent/IL141588A/en not_active IP Right Cessation
- 2001-03-14 HR HR20010188A patent/HRP20010188A2/hr not_active Application Discontinuation
- 2001-03-14 NO NO20011304A patent/NO20011304L/no not_active Application Discontinuation
-
2002
- 2002-01-08 HK HK02100128.3A patent/HK1040261A1/zh unknown
-
2003
- 2003-09-17 US US10/664,801 patent/US20040115199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL141588A (en) | 2008-07-08 |
| DE69924392T2 (de) | 2006-03-09 |
| CA2343654A1 (en) | 2000-03-23 |
| NZ510508A (en) | 2005-05-27 |
| KR20010085807A (ko) | 2001-09-07 |
| CN1318105A (zh) | 2001-10-17 |
| DE69924392D1 (de) | 2005-04-28 |
| HUP0103578A3 (en) | 2005-11-28 |
| EP1114166A1 (en) | 2001-07-11 |
| NO20011304L (no) | 2001-05-15 |
| CZ2001789A3 (cs) | 2001-08-15 |
| NO20011304D0 (no) | 2001-03-14 |
| ES2239457T3 (es) | 2005-09-16 |
| ATE291628T1 (de) | 2005-04-15 |
| PL346698A1 (en) | 2002-02-25 |
| TR200100737T2 (tr) | 2001-07-23 |
| ID28386A (id) | 2001-05-17 |
| HRP20010188A2 (en) | 2002-04-30 |
| JP2002525060A (ja) | 2002-08-13 |
| US20040115199A1 (en) | 2004-06-17 |
| AU754971B2 (en) | 2002-11-28 |
| US6645500B1 (en) | 2003-11-11 |
| IL141588A0 (en) | 2002-03-10 |
| AU5617399A (en) | 2000-04-03 |
| SK3062001A3 (en) | 2002-02-05 |
| PL196790B1 (pl) | 2008-01-31 |
| KR100671036B1 (ko) | 2007-01-18 |
| EP1114166B1 (en) | 2005-03-23 |
| HK1040261A1 (zh) | 2002-05-31 |
| HUP0103578A2 (hu) | 2002-01-28 |
| EE200100149A (et) | 2002-08-15 |
| WO2000015807A1 (en) | 2000-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1114166E (pt) | Metodo para regular negativamente a actividade do ligando da osteoprotegerina | |
| AR047392A1 (es) | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines | |
| WO2000075350A3 (en) | Nucleic acid sequences encoding proteins involved in fatty acid beta-oxidation and methods of use | |
| CA2241918A1 (en) | Peanut allergens and methods | |
| EA200900180A1 (ru) | Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном | |
| HUP0004611A2 (hu) | APRIL, egy új növekedési hatású fehérje | |
| EP1162272A3 (en) | Generation of immune responses to prostate-specific antigen (SPA) | |
| MX9708854A (es) | Terapia de genes para regulacion de celulas efectoras. | |
| ATE203413T1 (de) | IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG | |
| CA2272407A1 (en) | Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen | |
| ZA87141B (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
| BR9506272A (pt) | Análogo isolado e purificado de proteina hin 47 haemophilus influenzae moçécula quimérica molécula de ácido nucleico purificada e isolada plasmídeo recombinante célula tranformada processo para produzir um análogo de porteina hin 47 haemophilus influenzae composicão imunogênica processo para determinir a presença de anticorpos processo para determinir a presença de proteina hin 47 em uma amostra e estojo diagnóstico hin 47 | |
| NO20015021L (no) | Fremgangsmåte til å nedregulere IL-5 aktivitet | |
| WO2000030667A3 (en) | Compositions and methods using lactadherin or variants thereof | |
| YU19701A (sh) | Postupak za regulisanje na niže osteoprotegerinske ligandne aktivnosti | |
| WO1999047558A3 (en) | T cell costimulatory proteins, sequences and uses thereof | |
| EP1541587A3 (en) | Method for down-regulating osteoprotegerin ligand activity | |
| WO2002040059A3 (en) | Methods and compositions for inducing cell-mediated immune responses | |
| WO2001055410A3 (en) | Ceramidase compositions and methods based thereon | |
| JP2004535783A (ja) | 乾癬の治療及び臨床的寛解のための組成物及び方法 | |
| Murphy | Mechanism of apoptotic regulation of follicular regression: toward understanding the molecular basis for tissue remodeling and regeneration | |
| Rasmussen et al. | Repeated electroconvulsive shock selectively increases the expression of the neuron specific enolase in piriform cortex | |
| WO2002088380A3 (en) | Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof | |
| Ivanov | EXPERIMENTAL STUDIES OF THE INFLUENCE OF HIGH DOSES OF VITAMINS A AND Е ON THE 5'NUCLEOTIDASE AND ADENYLPYROPHATASE ACTIVITY AND ON THE QUANTITY OF THE THIOL GROUPS IN THE HEART MUSCLE OF WHITE RATS | |
| HUP0002511A2 (hu) | Neisseria eredetű, laktoferrinkötő fehérje |